Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.

Autor: Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Boissel N; Hématologie Clinique, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France., Papayannidis C; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy., Luskin MR; Division of Leukemia, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Stelljes M; Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Münster, Münster, Germany., Advani AS; Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ribera JM; Clinical Hematology Department, Institut Catalá d'Oncologia-Hospital Germans Trias i Pujol, Jose Carreras Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain., Marks DI; Bristol Haematology and Oncology Center, University Hospitals Bristol National Health Service Trust, Bristol, UK.

Publikováno v: Cancer [Cancer] 2024 Nov 01; Vol. 130 (21), pp. 3631-3646. Date of Electronic Publication: 2024 Aug 02.

Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.

Autor: Aldoss I; Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Roloff GW; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Faramand R; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL., Kopmar NE; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Lin C; Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC., Advani AS; Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH., Dekker SE; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.; Division of Hematology-Oncology, Oregon Health Science, Portland, OR., Gupta VK; Division of Hematology & Oncology, University of California, Los Angeles, CA., O'Connor TE; Division of Hematology/Oncology, Loyola University Medical Center, Maywood, IL., Jeyakumar N; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Muhsen IN; Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX., Valtis Y; Department of Hematology and Oncology, Memorial Sloan Kettering Cancer Institute, New York, NY., Zhang A; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Miller K; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Sutherland K; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Dykes KC; Department of Medicine, Division of Hematology and Oncology, University of California, San Diego, CA., Ahmed M; Department of Hematology and Oncology, Cedars Sinai Medical Center, Los Angeles, CA., Chen E; Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA., Zambrano H; Department of Transplant and Cellular Therapy, Sarah Cannon Cancer Institute, Tampa, FL., Bradshaw D; Department of Medicine, Division, Hematology and Oncology, Georgia Cancer Center at Augusta University, Augusta, GA., Mercadal S; Transplant and Cellular Therapy Program, University of Utah, Huntsman Cancer Hospital, Salt Lake, UT., Schwartz M; Department of Hematology and Oncology, University of Colorado, Anschutz Medical Center, Aurora, CO., Tracy S; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Dholaria B; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Kubiak M; Department of Medicine, Division, Hematology and Oncology, Georgia Cancer Center at Augusta University, Augusta, GA., Mukherjee A; Department of Hematology and Oncology, Oncology Hematology Care, Cincinnati, OH., Majhail N; Department of Transplant and Cellular therapy, Sarah Cannon Cancer Institute, Nashville, TN., Battiwalla M; Department of Transplant and Cellular therapy, Sarah Cannon Cancer Institute, Nashville, TN., Mountjoy L; Department of Lymphoma, Colorado Blood Cancer Institute, Denver, CO., Malik SA; Center for Blood Cancer and Oncology, Texas Transplant Institute, Austin, TX., Mathews J; Department of Transplant and Cellular Therapy, Sarah Cannon Cancer Center, Midland, TX., Shaughnessy P; Department of Transplant and Cellular Therapy, Sarah Cannon Cancer Center, San Antonio, TX., Logan AC; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA., Ladha A; Department of Hematology, University of Southern California, Los Angeles, CA., Stefan M; Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH., Guzowski C; Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA., Hoeg RT; Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis, CA., Hilal T; Division of Hematology and Medical Oncology, Mayo Clinic, Rochester, MN., Moore J; Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY., Connor M; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., O'Dwyer KM; Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY., Hill LC; Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX., Tsai SB; Division of Hematology/Oncology, Loyola University Medical Center, Maywood, IL., Sasine J; Department of Hematology and Oncology, Cedars Sinai Medical Center, Los Angeles, CA., Solh MM; Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA., Lee CJ; Transplant and Cellular Therapy Program, University of Utah, Huntsman Cancer Hospital, Salt Lake, UT., Kota VK; Department of Medicine, Division, Hematology and Oncology, Georgia Cancer Center at Augusta University, Augusta, GA., Koura D; Department of Medicine, Division of Hematology and Oncology, University of California, San Diego, CA., Veeraputhiran M; Department of Hematology and Oncology, University of Arkansas Medical Center, Little Rock, AR., Blunk B; Department of Transplant and Cellular therapy, Sarah Cannon Cancer Institute, Nashville, TN., Oliai C; Division of Hematology & Oncology, University of California, Los Angeles, CA., Leonard JT; Division of Hematology-Oncology, Oregon Health Science, Portland, OR., Frey NV; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Park JH; Department of Hematology and Oncology, Memorial Sloan Kettering Cancer Institute, New York, NY., Luskin MR; Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA., Bachanova V; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Galal A; Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC., Bishop MR; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Stock W; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Cassaday RD; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Pullarkat V; Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Shah BD; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL., Muffly LS; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA.

Publikováno v: Blood advances [Blood Adv] 2024 Dec 10; Vol. 8 (23), pp. 6139-6147.

Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059.

Autor: Wu JH; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Pennesi E; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Bautista F; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Garrett M; Pfizer Global Pharmacometrics, San Diego, CA, USA., Fukuhara K; Pfizer R&D Japan, Tokyo, Japan., Brivio E; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Ammerlaan ACJ; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Locatelli F; Department of Hematology, Oncology and of Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesú, Catholic University of the Sacred Heart, Rome, Italy., van der Sluis IM; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Rossig C; Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany., Chen-Santel C; Department of Pediatrics, Division of Oncology and Hematology, Charité-Universitätsmedizin Berlin, German Cancer Consortium (DKTK) site Berlin, National Center for Tumor diseases (NCT) site Berlin, Berlin, Germany., Bielorai B; Division of Pediatric Hematology and Oncology, Sheba Medical Center, Ramat-Gan, Israel., Petit A; Department of Pediatric Hematology and Oncology, Hopital Armand Trousseau, APHP, Sorbonne Université, Paris, France., Starý J; Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic., Díaz-de-Heredia C; Division of Pediatric Hematology and Oncology. Hospital, Universitari Vall d'Hebron, Barcelona, Spain., Rives S; Pediatric Oncology and Hematology Department, Hospital Sant Joan de Déu de Barcelona, Barcelona, Spain.; Institut de Recerca Sant Joan de Déu, Barcelona, Spain., O'Marcaigh A; Children's Health Ireland at Crumlin, Dublin, Ireland., Rizzari C; Pediatric Hematology-Oncology Unit, Department of Pediatrics, IRCCS Foundation San Gerardo dei Tintori, Monza and University of Milano-Bicocca, Monza, Italy., Engstler G; St Anna Children's Hospital, Medical University of Vienna, Vienna, Austria., Nysom K; Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark., Rubio-San-Simón A; Department of Pediatric Oncology and Hematology, Hospital Niño Jesús, Madrid, Spain., Bruno B; Pediatric Hematology, Hôpital Jeanne de Flandre, , CHRU de Lille, Lille, France., Bertrand Y; Institute of Pediatric Hematology and Oncology, Civil Hospital of Lyon, Claude Bernard University, Lyon, France., Brethon B; Department of Pediatric Hematology, Hôpital Robert-Debré, Assistance Publique-Hôpitaux de Paris, Paris, France., Rialland F; Service Onco-Hématologie Pédiatrique, Hôpital Mère-Enfant, Nantes University Hospital, Nantes, France., Plat G; Service d'Hématologie-Immunologie-Oncologie, Hôpital des Enfants, CHU Toulouse, Toulouse, France., Dirksen U; Pediatrics III, University Hospital Essen, German Cancer Consortium (DKTK) Site Essen, Essen, Germany., Sramkova L; Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic., Zwaan CM; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital Rotterdam, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands. c.m.zwaan-2@prinsesmaximacentrum.nl.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. c.m.zwaan-2@prinsesmaximacentrum.nl., Huitema ADR; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.

Publikováno v: Clinical pharmacokinetics [Clin Pharmacokinet] 2024 Jul; Vol. 63 (7), pp. 981-997. Date of Electronic Publication: 2024 Jun 22.

Anti-CD22 Calicheamicin-Inotuzumab Ozogamicin Combined with Venetoclax + Azacitidine in the Treatment of Mixed-Phenotype Acute Leukemia: A Case Report

Autor: Li K; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, China; Ningbo University, Institute of Hematology, Department of Hematology, Ningbo, China, Wang Y; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, China; Ningbo University, Institute of Hematology, Department of Hematology, Ningbo, China, Pei R; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, China; Ningbo University, Institute of Hematology, Department of Hematology, Ningbo, China, Lu Y; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, China; Ningbo University, Institute of Hematology, Department of Hematology, Ningbo, China, Cao J; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, China; Ningbo University, Institute of Hematology, Department of Hematology, Ningbo, China, Zhuang X; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, China; Ningbo University, Institute of Hematology, Department of Hematology, Ningbo, China, Lian J; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, China; Ningbo University, Institute of Hematology, Department of Hematology, Ningbo, China, Zhang B; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, China; Ningbo University, Institute of Hematology, Department of Hematology, Ningbo, China

Publikováno v: Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2024 Aug 28; Vol. 41 (3), pp. 202-204. Date of Electronic Publication: 2024 Jul 30.

Bone marrow necrosis and hyperinflammation after treatment with inotuzumab ozogamicin for B-cell acute lymphoblastic leukaemia.

Autor: Marcoux C; Division of Haematology, Department of Medicine, Dalhousie University, Halifax, NS, Canada. Electronic address: Curtis.Marcoux@nshealth.ca., Thakkar P; Division of Haematology, Department of Medicine, Dalhousie University, Halifax, NS, Canada., Conrad DM; Division of Haematopathology, Department of Pathology, Dalhousie University, Halifax, NS, Canada., Shawwa AA; Division of Haematopathology, Department of Pathology, Dalhousie University, Halifax, NS, Canada., Chen LYC; Division of Haematology, Department of Medicine, Dalhousie University, Halifax, NS, Canada; Division of Haematology, Department of Medicine, Vancouver, BC, Canada.

Publikováno v: Lancet (London, England) [Lancet] 2024 Sep 28; Vol. 404 (10459), pp. 1253-1254.